NEFL and Alzheimer disease: The primary objective of this study was to assess the performance of combined plasma biomarkers, including plasma Aβ42/40 ratios, plasma p-tau181, and plasma NFL to identify older adults who are suitable candidates to receive AD therapeutics: early-stage AD patients (those with MCI or mild AD) with positive amyloid pathology.